Ertugliflozin L-pyroglutamic acid is a pharmaceutical compound that is a specific salt form of ertugliflozin, an antidiabetic medication used primarily to manage type 2 diabetes.

Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which works by preventing the kidneys from reabsorbing glucose back into the blood. Instead, glucose is excreted through the urine, which helps lower blood sugar levels.

The addition of L-pyroglutamic acid to the molecule forms a salt, which can improve certain properties of the drug, such as its stability, solubility, or absorption in the body. In the pharmaceutical industry, creating a salt form of a drug is a common strategy to enhance the drug's effectiveness and make it easier to formulate.

This particular salt form, ertugliflozin L-pyroglutamic acid, is used in some formulations to optimize the drug's performance, ensuring that it is more efficient and stable for therapeutic use.